Adcentrx Therapeutics to Present First Clinical Data for ADRX-0706 Nectin-4 ADC at ASCO 2025
Interim results from Phase 1a dose escalation to be presented
Data provide clinical proof of concept for Adcentrx's novel technology platform; highlight unique opportunity for ADRX-0706 to address significant unmet needs for patients with limited therapeutic options
SAN DIEGO, April 23, 2025 /PRNewswire/ — Adcentrx Therapeutics ('Adcentrx'), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, will present the first clinical data for ADRX-0706 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 – June 3, 2025) in Chicago, IL.
Adcentrx will deliver a poster presentation on ADRX-0706, a clinical-stage Nectin-4 ADC. The presentation will include interim clinical data from the Phase 1a portion of the ongoing trial (NCT06036121), demonstrating the best-in-class potential for ADRX-0706. The findings indicate a differentiated safety and pharmacokinetic profile, including a significantly lower incidence of critically meaningful adverse events such as peripheral neuropathy. Additionally, preliminary efficacy signals across different dose levels and tumor types provide strong clinical validation of Adcentrx's ADC platform, including the i-Conjugation® technology and novel auristatin payload AP052.
The first-in-human Phase 1a/b study is an open-label, two-part trial being conducted at sites in the U.S. and China. The completed Phase 1a portion consisted of a dose escalation of ADRX-0706 to evaluate initial safety and tolerability in patients with select advanced solid tumors, and to identify the recommended dose to be used in Phase 1b. This ongoing second portion of the study aims to further evaluate ADRX-0706's safety and tolerability, preliminary efficacy, and optimal dose in urothelial, triple-negative breast and cervical cancers.
Details of the poster presentation at the ASCO Meeting are as follows:
Title: Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next generation Nectin-4 ADC, in subjects with advanced solid tumorsAbstract Number: 3018Session Date & Time: Monday, June 2, 1:30 p.m. – 4:30 p.m. CSTSession Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
The full abstract will be published by ASCO in conjunction with the Meeting.
About i-Conjugation® TechnologyAdcentrx's proprietary i-Conjugation® technology platform is a core component in the design of the company's ADCs. The platform utilizes protease-cleavable linkers and stable conjugation chemistry to enhance payload delivery. This advanced technology ensures a highly stable ADC with the desired linker-payload.
About ADRX-0706ADRX-0706 is a fully proprietary ADC product candidate discovered by Adcentrx. The antibody component is a novel fully human IgG1 targeting Nectin-4, a cell surface adhesion protein with high expression in multiple solid tumors and limited expression in normal tissues. Nectin-4 is associated with poor disease prognosis and is a validated target for ADCs.
The ADRX-0706 antibody is linked to a proprietary tubulin inhibitor payload, AP052, through Adcentrx's innovative i-Conjugation® technology using a cleavable linker and stable conjugation chemistry. This novel platform technology enables a highly stable ADC with a drug-antibody ratio of eight (DAR 8) with a substantially expanded therapeutic window as demonstrated in preclinical studies.
ADRX-0706 has a favorable pharmacokinetic and safety profile in preclinical models and has demonstrated significant efficacy across a variety of tumor indications in vitro and in vivo. ADRX-0706 is currently being evaluated in a Phase 1a/b clinical trial.
For more information about the ADRX-0706 Phase 1a/b clinical trial, please refer to the Study ID NCT06036121 on ClinicalTrials.gov.
About Adcentrx TherapeuticsAdcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. Adcentrx has pioneered the development of an ADC technology platform addressing key components of protein conjugate design to solve challenges typically seen in ADCs. Adcentrx is developing a robust pipeline including two clinical-stage ADCs and multiple preclinical ADCs, all with first-in-class and best-in-class potential.
For more information about Adcentrx and its innovative ADC technologies, please visit https://adcentrx.com.
Contact Information:Investor Relationsir@adcentrx.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
7 minutes ago
- Malaysian Reserve
Above Food Ingredients Inc. Meets Compliance Requirements
REGINA, SK, June 6, 2025 /PRNewswire/ – Above Food Ingredients Inc. (NASDAQ: ABVE) ('the Company'), acknowledges receipt of a formal notification from The Nasdaq Stock Market LLC regarding non-compliance with Listing Rule 5450(b)(3)(C), regarding minimum market value of publicly held shares (PR market value). The company is very pleased that this condition has been met as of May 27, 2025. Furthermore, the Company is very pleased that, as of May 27, 2025, it has met Listing Rules 5810(c)(3)(A) and 5450(a)(1) requirements as well, and the Company is awaiting confirmation from the NASDAQ for Compliance Determination. As of Spring 2025, the Company has made great strides with the restructuring of the operations and its pursuit of maximising shareholder value. Meeting compliance with the NASDAQ listing requirements is another milestone achieved in allowing the company to continue executing on its strategic plan. The Company will continue to inform shareholders of its advancements over the next coming weeks. Above Food Ingredients Inc. (Nasdaq: ABVE ) is an ingredient company that delivers products made with real, nutritious, flavorful ingredients produced with transparency. The Company's vision is to create a healthier world — one seed, one field, and one bite at a time. With a robust chain of custody of plant proteins, enabled by scaled operations and infrastructure in primary agriculture and processing, and proprietary seed development capabilities that leverage the power of artificial intelligence-driven genomics and agronomy, the Company delivers nutritious ingredients to businesses and consumers with traceability and sustainability. This press release may contain 'forward-looking information' within the meaning of the United States federal securities laws and applicable Canadian securities laws. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'could,' 'will be,' will continue,' and similar expressions and include, without limitation, statements about the ability of or expectations regarding the future performance of our business and operations. Forward-looking statements are based on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. You should carefully consider all of the risks and uncertainties described in the documents filed by the Company with the United States Securities and Exchange Commission, which is available on EDGAR at There may be additional risks that the Company presently does not know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in forward-looking statements. In addition, forward-looking statements provide the Company's expectations, plans or forecasts of future events and views as of the date of this communication. The Company anticipates that subsequent events and developments will cause the Company's assessments to change. However, while the Company may elect to update these forward-looking statements in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's assessments as of any date subsequent to the date of this communication. Nothing herein should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results in such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Biorn Corporation Doubles Down on Results: Proven Recovery Solutions Now Available for Your Hardest-to-Collect Accounts
FORT LAUDERDALE, Fla., June 6, 2025 /PRNewswire/ — In an industry where trust and performance matter most, Biorn Corporation, a results-driven debt collection agency with over four decades of leadership, is inviting new clients to experience what many are already calling the 'Biorn Difference.' Led by veteran collector Craig Biorn, the agency recently recovered over 17% on aged, previously uncollectable accounts for a national agricultural client—proving that even 'dead-end debt' can be turned into real dollars with the right team and method. 'In today's economy, credit managers need more than reminders—they need results,' said Biorn. 'We don't just chase payments. We use tested strategies, personal accountability, and sharp analysis to recover what others walk away from.' 'Inspecting what our people do makes them better,' Biorn adds. 'Our team is built to win, and to win for our clients.' Why Credit Managers Are Turning to Biorn: Second Placements Welcome – Let us recover what your first agency couldn't. Nationwide Coverage – We serve clients across industries, from agriculture to manufacturing. Transparent Reporting – You'll always know where your money is. Tailored Approach – No cookie-cutter tactics—just smart, compliant, effective collection strategies. Let's Talk RecoveryIf you're a credit manager, CFO, or business owner looking to improve recovery rates or try a new approach, Biorn Corporation invites you to a free consultation. Let us evaluate your current accounts and show you what a second look can really mean. Contact:Craig Biorn, President or Grey Luna, Vice President of Sales754-277-2870396242@ Diamond Executive Building- Fort Lauderdale, Florida
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Haier's Strategic Partnership with Roland-Garros Enters Third Year, Driving Shared Values of Excellence
PARIS, June 6, 2025 /PRNewswire/ — As the 2025 Roland-Garros (French Open) enters its final stretch, the iconic clay courts of Paris are once again alive with the intensity and elegance that define the Grand Slam. At the heart of this prestigious tournament, Haier celebrates the third year of its strategic partnership with Roland-Garros, first launched in 2023. This enduring collaboration reflects a shared commitment to excellence, innovation, and resilience, values that resonate both on the court and across Haier's global vision for premium living. Forging Strength and Grace: A Shared Journey of Excellence While every Grand Slam tournament tests a player's determination and skill, Roland-Garros stands apart for its demand for finesse, resilience, and endurance on clay. Similarly, Haier's journey in building a global brand began in 1990 and it took 25 years of unwavering commitment to achieve financial self-balance in overseas markets, reflecting the endurance and long-term vision that define both sport and business. Beyond endurance, Roland-Garros stands as a beacon of global prestige and refined standards, while Haier has cultivated a reputation as a leading high-end brand in Europe. Together, they embody a powerful synergy of perseverance and sophistication on the global stage. Where Heritage Meets Innovation: Haier's Premium Presence in France As global momentum toward intelligent and sustainable innovation accelerates, the 2025 AI Action Summit in Paris exemplifies a shared international ambition for inclusive, energy-efficient, and human-centered technology. In this context, Haier continues to lead the way. In France, Haier's Langjing X11 washing machine exemplified its commitment, delivering 60% energy savings compared to Europe's rigorous A-class standards—a critical advantage amid rising energy concerns. With premium pricing (reflected in a price index of 275 in Poland and 375 in the UK), the Langjing X11 reinforces Haier's innovative, high-end positioning. In 2024, Haier achieved 47% brand awareness in France, highlighting its growing influence among discerning consumers. Strategic Expansion of Haier in Europe: Deep Roots and Localized Excellence The success of Haier in France is the result of a long-term commitment to deep localization and strategic expansion across Europe. Since entering Germany in the 1990s, Haier has built a strong and steady presence across the continent, driven by a consistent focus on innovation and user needs. At the core of the European growth of Haier is the 3-in-1 strategy (localized R&D, manufacturing, and marketing), enabling the brand to respond quickly and effectively to local demand. For instance, in the European market where air conditioner penetration remains below 5%, Haier introduced a smart air solution with simplified installation to meet local needs with precision and efficiency. The spirit of persistence and dedication to innovation, grounded in a deep understanding of local markets, has propelled the steady rise of Haier across multiple European countries. Haier continues to lead in Europe. This success story reflects the ongoing dedication of Haier to innovation and localization, anchored by the 3-in-1 strategy, which continues to drive its strong market presence and recognition, with brand awareness reaching approximately 30% across Europe in 2024. Haier ESG Commitment: Empowering a Greener, More Inclusive Future The partnership between Haier and Roland-Garros goes beyond the court and represents a shared commitment to promoting healthy lifestyles, advancing social responsibility, and creating sustainable value for communities across the globe. At Roland-Garros, Haier brought its ESG values to life through an immersive pop-up experience, showcasing its latest advancements in sustainable technology. Demonstrating a firm commitment to nurturing the next generation, Haier partnered with Open Stade Français to launch the 'Haier Fans Cup', offering young winners the unique opportunity to attend the tournament and meet former WTA Number one champion Ana Ivanovic. Further reflecting its people-centric and innovation-driven approach, Haier France was awarded the Gold certification for Great Onboarding from Workelo, demonstrating its dedication to building a future-ready workplace. From homes to communities, from sustainable technologies to human-centered governance, Haier is setting a new standard for global brands. Photo – View original content:
